Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olanzapine + samidorphan l-malate
- Development stage
- Approved
- Lead developer
- Alkermes
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Olanzapine + samidorphan l-malate is an oral fixed-dose combination antipsychotic marketed as **LYBALVI** that combines olanzapine, a multi-receptor atypical antipsychotic whose therapeutic activity in schizophrenia and bipolar I disorder is primarily attributed to dopamine and serotonin receptor antagonism, with samidorphan as samidorphan l-malate, an opioid receptor antagonist added to mitigate olanzapine-associated weight gain. The product was developed for adults with schizophrenia and bipolar I disorder, including acute manic or mixed episodes and maintenance treatment in bipolar I disorder. It is supplied as once-daily film-coated bilayer tablets in multiple strengths containing olanzapine with a fixed 10 mg samidorphan component.
- Brand names
- LYBALVI
- Other names
- olanzapine + samidorphan l-malateolanzapine and samidorphanolanzapine + samidorphan
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR3A (5-hydroxytryptamine receptor 3A)ADRA1A (α1A)DOR (Opioid Receptor Delta 1)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)CHRM5 (M5)
Beyond the preview
Go deeper on olanzapine + samidorphan l-malate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olanzapine + samidorphan l-malate.